Novigenix Acquires Blood-Based Molecular Diagnostics Test Colox® and Prepares Its Further Commercial Rollout in Switzerland and Europe to Improve the Early Detection of Colorectal Cancer

LAUSANNE, Switzerland--()--Molecular diagnostics company Novigenix SA announced today it acquired Colox®, a new molecular blood test for the detection of colorectal cancer and pre-cancerous lesions (adenomatous polyps). Colox has been approved for sale in Europe, and has been launched commercially in Switzerland. Novigenix aims to increase the availability of Colox in Switzerland and Europe through partnerships.

Brian Hashemi, Executive Chairman of Novigenix SA, said: “Our vision is to support physicians and the healthcare community in significantly reducing cancer mortality through the early diagnosis and intervention of colorectal cancer. We are committed to making Colox available to physicians and patients across Switzerland, followed by expansion in other European countries. Colorectal cancer is today the third most lethal cancer, but can be largely prevented if detected early by an accurate, reliable, and convenient test such as Colox.”

Colox has been tested in a multi-center clinical study in Switzerland led by Professor Gian Dorta, MD, in Internal Medicine Department, at the Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, Lausanne (CHUV). “Colox accurately and reliably detects both adenomatous polyps and early stages of colorectal cancer with a convenient blood test that can be ordered as part of a routine medical checkup. As a result Colox has the potential to dramatically increase screening compliance and reduce the mortality rate from this deadly disease,” said Professor Dorta.

Colox, originally developed by Diagnoplex SA, represents a new generation of cancer diagnostic tests based on the response of the organism against the tumor. Peripheral Blood Mononuclear Cells (PBMCs) are particularly responsive to growing adenomatous polyps and colorectal carcinomas. Determining the expression of 29 genes in PBMCs provides a telltale sign of the early stages of colorectal cancer. Gene expression data are interpreted by Novigenix’s proprietary algorithm which generates the Colox test report. This algorithm is based on classifier combinations derived from mathematical analytical methods that underpin the reliability of the test.

About Novigenix SA:

Novigenix SA is an innovative Swiss molecular diagnostics company focused on the commercialization of new screening and diagnostics tools for early detection of cancer. Novigenix’s products rely on a new generation of predictive molecular signatures and state-of-the-art mathematical analytical models to provide new solutions for the early diagnosis of cancer. For more information please visit www.novigenix.com

About Colox®:

Colox® is a proven molecular blood test that has been designed to support the healthcare community in significantly reducing mortality from colorectal cancer through early diagnosis and intervention. This convenient blood test can be ordered by a physician during a routine medical checkup to accurately and reliably detect both adenomatous polyps and early stages of colorectal cancer. Colox is available as a Laboratory Developed Test and is highly suited to standard medical laboratory workflow. Colox is also available as a CE registered kit.

NOTE: Colox® has been approved for sale in Europe. It is not yet approved for use in the United States.

Contacts

Novigenix SA
Christian Jauch, Director of Finance
Christian.Jauch@novigenix.com
Cell: +41 79 768 38 20

Website